Dr Ian Nisbet: Ledger

Stories naming Dr Ian Nisbet. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Role	Organisation	Sources
CEO	Cartherics	Wholesale Investor

News

Off-the-Shelf, On-the-Money: How a Melbourne Biotech is Expanding its Oncology Platform to Endometriosis

Profile of Melbourne biotech Cartherics, which is extending its off-the-shelf cell therapy platform from ovarian cancer to endometriosis; its CEO outlines a capital raise in progress and 2026 clinical trial plans.

Wholesale Investor 7 Apr 2026 Cartherics Emergence 2026 Professor Alan Trounson Dr Ian Nisbet

Funding announcement

Verva Pharmaceuticals Signs Deals with Two Biotechs

Australian diabetes biotech Verva sold all its IP to two biotechs and entered liquidation with PKF Australia appointed; background recalls early Adipogen backing from Uniseed, QIC BioVentures and GBS Ventures.

GBS Ventures 20 Jul 2015 Chemgenex GBS Ventures SYNthesis Med Chem UniQuest Uniseed University of Queensland Verva Pharmaceuticals Limited Dr Ian Nisbet

Dr Ian Nisbet

Roles

Coverage

Off-the-Shelf, On-the-Money: How a Melbourne Biotech is Expanding its Oncology Platform to Endometriosis

Verva Pharmaceuticals Signs Deals with Two Biotechs